Drug Trial Radar · NCT07770828
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
237
Planned (sponsor's estimate)
Start
Aug 11, 2026
Primary completion
Jul 30, 2028
Study completion Jul 30, 2031
Sponsor
- Lead sponsor
- OcugenIndustry
- Sponsor type
- Industry
- First posted
- Aug 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm
Conditions
- Dry Age-related Macular Degeneration
Interventions
OCU410Biological
Subretinal Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of change (slope) of square root-transformed GA lesion area from baseline to Month 12Time frame: Month 12
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
associated Retina Consultants
Phoenix, Arizona · Not yet recruiting
Erie Retina Research
Erie, Pennsylvania · Not yet recruiting
Valley Retina Institute
McAllen, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.